

 TransEnterix®



Todd M. Pope
President & CEO

Wells Fargo Healthcare Conference

September 6, 2018

Forward Looking Statements


This presentation includes statements relating to the Senhance™ Surgical System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the commercialization of the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons, the success and market opportunity of our products, our current cash reach, the effect on our business of existing and new regulatory requirements and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 8, 2018 and other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of the presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.






At TransEnterix, we believe in **digitizing the interface between the surgeon and patient in laparoscopy** to **increase control and reduce surgical variability** in today's value-based healthcare environment


TransEnterix: TRXC






SenhanceSurgery

Surgical Robotics Poised for Growth



Robotic Surgery Landscape

**Current
abdominal
robotic surgery**



700k procedures
EU & U.S.

**Open
Surgery**

4 MM
procedures
EU & U.S.

**Laparoscopic
Surgery**


6 MM procedures
EU & U.S.

Historical Growth Drivers:

- Convert open surgeries to robotics
- Offset significant per-procedure cost increase with length of stay benefit vs. open surgery



Digital Laparoscopy Opportunity



Future Growth Drivers

- Convert laparoscopic surgeries to robotics
- Improve laparoscopy: designed for greater precision, efficiencies, safety, ergonomics
- Provide meaningful robotic benefits to laparoscopic surgery without significant per procedure cost increase



Need for Robotic System that Addresses the Laparoscopic Market

Laparoscopy is Widespread

- Familiar motion and approach
- Completed learning curve
- Significant investments in laparoscopic ecosystem

Limitations of Laparoscopy

- Reliance on assistant to control camera
- Challenging ergonomics
- Imprecise instrument movement
- Torque at incision sites

Hospitals Under Pressure

- Robotics has added procedure costs
- Hospitals feel pressured to offer robotic option or lose volume
- Majority of surgeons now hospital employees, need to retain and extend productivity



Senhance Delivers Value to All Constituents

Value to Surgeons

- Enables surgeon to control vision
- Improved ergonomics
- Familiar lap technique
- Rapid docking for ease of setup
- Ease of patient repositioning

Value to Patients

- Focused on reducing patient trauma in surgery
- Retain 5mm instruments
- Moving to 3mm instruments
- Security of haptic feedback
- Minimize incisional pain

Value to Hospitals


- Parity to laparoscopy in per-procedure cost
- Surgeon recruiting and retention
- Patient recruitment
- Leverage current investments in laparoscopic ecosystem



Senhance Robotic Inguinal Hernia Repair
Left side, TAPP, Lateral and Medial Hernias

Dr. Dietmar Stephan, St. Marien Krankenhaus
Siegen, Germany


Department of Minimally Invasive and Robotic Surgery
Clinic of General Surgery, Chief Prof. Dr. F. Willeke



Senhance Commercialization

Early Commercial Momentum

Total Revenue (\$M) and System Sales



Strategy for Driving Continued Adoption

Broaden Applicability of Senhance



Increase Surgeon Interaction with Senhance



Optimize Global Salesforce



Broaden Applicability – U.S. Indications for Use

1.5 million

Gynecologic
Colorectal

Initial Addressable
Procedures – 4Q17

> 3 million

Inguinal Hernia
Gallbladder


Gynecologic
Colorectal

Expanded Addressable
Procedures – 2Q18



Broaden Applicability - Instrumentation

3mm "Microlap"




- Enables virtually scarless surgery
- First robotically enabled 3mm platform

Advanced Energy



- Enable access to more surgeons and procedures
- Opens access to multi-billion dollar market


Articulating



- Increase degrees of freedom
- Minimizes incision size with 5mm platform



Broaden Applicability – Geographic Expansion



- **Taiwan**

- Senhance System currently approved by Taiwan FDA
- Expect instrument approvals by end of 2018

- **Japan**

- Established subsidiary in 2Q18
- Pursuing Japanese PMDA Approval for Senhance



Increase Surgeon Interaction with Senhance

Installed Base Growth




- Increased opportunities for surgeons to observe surgery
- Multiple active systems in each geographic segment - EMEA, Asia, and U.S.

Mobile Events



- Bringing Senhance directly to hospitals and surgeons in EMEA and U.S.
- Opportunities for surgeons to demo system in multiple settings

Conference Attendance



- Senhance demonstrations and hands-on experience for surgeons and hospital admins
- ACS, AAGL, SAGES, DGCG, EAES



Optimize Global Salesforce

Appointment of Chief Commercial Officer – 3Q18



U.S.



- Direct salesforce ~15 reps
- Plan to increase reps to provide greater coverage



EMEA



- Mix of Direct & Distributor
- Shifting more resources to distributors



Asia



- Established Japanese subsidiary to manage development of sales infrastructure





Financial Overview

- 2017 Revenue: ~ \$7.0 million
 - ✓ 360% increase over 2016
- 1H 2018 Revenue: ~\$11.2 million
 - ✓ 215% increase over 1H 2017
- June 30, 2018 Balance Sheet Highlights
 - ✓ Cash & Restricted Cash ~ \$99 million
 - ✓ Debt ~ \$20 million, ability to add incremental \$20 million
 - ✓ Cash sufficient to fund business into 2020



TransEnterix: TRXC





 TransEnterix®